Prime Minister Narendra Modi on Sunday (December 22, 2024) left for home after wrapping up his two-day "successful" visit to Kuwait during which the two countries elevated their relationship to a strategic partnership , marking a new era of bilateral cooperation and growth. "Thank you Kuwait! This visit was historic and will greatly enhance our bilateral relations. I thank the Government and people of Kuwait for their warmth. I also thank the PM of Kuwait for the special gesture of coming to the airport for the see-off," Mr. Modi said in a post on X. Mr. Modi's visit to Kuwait was the first by an Indian Prime Minister to the Gulf nation in 43 years. In a special gesture, Kuwaiti Prime Minister Ahmad Abdullah Al-Ahmad Al-Sabah came to see off Mr. Modi at the airport as he left for India. "A historic & successful visit to Kuwait concludes! PM @narendramodi emplanes for New Delhi," Ministry of External Affairs Spokesperson Randhir Jaiswal said in a post on X. During his visit, Mr. Modi held extensive talks with the country's top leadership , including Emir Sheikh Meshal Al-Ahmad Al-Jaber Al-Sabah, with whom he discussed boosting ties in information technology, pharmaceuticals, fintech, infrastructure and security. "In line with the close ties between our nations, we have elevated our partnership to a strategic one and I am optimistic that our friendship will flourish even more in the times to come," Mr. Modi said in a post on X. Mr. Modi held wide-ranging talks with Kuwaiti Prime Minister Ahmad Abdullah Al-Ahmad Al-Sabah and Crown Prince Sabah Al-Khaled Al-Hamad Al-Mubarak Al-Sabah with a focus on giving new momentum to the overall bilateral ties. Kuwait also conferred its highest honour — 'The Order of Mubarak Al-Kabeer' — on Prime Minister Modi for his role in strengthening the good relations between the two countries. On Saturday, Mr. Modi addressed an Indian community event and visited an Indian labour camp. The over one million-strong Indian community is the largest expatriate community in Kuwait. The Gulf nation is among India's top trading partners, with bilateral trade valued at $10.47 billion in the financial year 2023-24. Kuwait is India's sixth largest crude supplier, meeting 3% of the country's energy needs. Indian exports to Kuwait reached $2 billion for the first time, while investments by the Kuwait Investment Authority in India exceeded $10 billion. Published - December 22, 2024 09:07 pm IST Copy link Email Facebook Twitter Telegram LinkedIn WhatsApp Reddit Kuwait / India / diplomacy / Prime Minister Narendra ModiNon-Cystic Fibrosis Bronchiectasis Pipeline Insights 2024: Therapies, Clinical Trials, and Key Companies Involved by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici 12-23-2024 11:12 PM CET | Business, Economy, Finances, Banking & Insurance Press release from: ABNewswire (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Non-Cystic Fibrosis Bronchiectasis pipeline constitutes 15+ key companies continuously working towards developing 15+ Non-Cystic Fibrosis Bronchiectasis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. The Non-Cystic Fibrosis Bronchiectasis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. "Non-Cystic Fibrosis Bronchiectasis Pipeline Insight, 2024 [ https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Cystic Fibrosis Bronchiectasis Market. Some of the key takeaways from the Non-Cystic Fibrosis Bronchiectasis Pipeline Report: * Companies across the globe are diligently working toward developing novel Non-Cystic Fibrosis Bronchiectasis treatment therapies with a considerable amount of success over the years. * Non-Cystic Fibrosis Bronchiectasis companies working in the treatment market are NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others, are developing therapies for the Non-Cystic Fibrosis Bronchiectasis treatment * Emerging Non-Cystic Fibrosis Bronchiectasis therapies in the different phases of clinical trials are- NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others are expected to have a significant impact on the Non-Cystic Fibrosis Bronchiectasis market in the coming years. * In December 2024, Armata Pharmaceuticals, Inc. (NYSE American: ARMP), a biotechnology company dedicated to developing high-purity, pathogen-specific bacteriophage therapeutics for chronic pulmonary diseases and antibiotic-resistant bacterial infections, today announced promising topline results from its Phase 2 "Tailwind" trial. The trial evaluated AP-PA02, a novel inhaled multi-phage therapeutic for treating chronic pulmonary Pseudomonas aeruginosa (P. aeruginosa) infections in patients with non-cystic fibrosis bronchiectasis (NCFB). * In May 2024, Insmed's stock more than doubled following the announcement that its lead pipeline candidate, brensocatib, successfully completed a Phase III trial. The much-anticipated ASPEN trial (NCT04594369) was a global, randomized, double-blind, placebo-controlled Phase III study designed to evaluate the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. * In July 2023, Zambon, a global pharmaceutical company dedicated to innovating treatments and enhancing the health and well-being of patients, revealed the conclusive findings from the Phase 3 PROMIS-I and PROMIS-II studies. These results were unveiled during the 2023 6th World Bronchiectasis Conference held in New York, NY. Non-Cystic Fibrosis Bronchiectasis Overview Non-cystic fibrosis bronchiectasis is a chronic lung condition characterized by the permanent widening and damage of the airways in the lungs, which leads to persistent coughing, excessive mucus production, and frequent respiratory infections. Unlike cystic fibrosis, it is not caused by a genetic defect in the CFTR gene. Non-cystic fibrosis bronchiectasis can result from various underlying conditions such as chronic infections, immune system disorders, or other lung diseases. Symptoms include chronic cough, shortness of breath, and fatigue. Treatment typically involves antibiotics to manage infections, bronchodilators, and airway clearance techniques to reduce symptoms and improve lung function. Get a Free Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight [ https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Emerging Non-Cystic Fibrosis Bronchiectasis Drugs Under Different Phases of Clinical Development Include: * NP339: NovaBiotics Ltd * Research Programme:NCFB: Synspira Therapeutics * Research programme: mucolytic agents: Parion Sciences * CHF 6333: Chiesi Farmaceutic * CSL787: CSL Behring * HSK31858: Haisco Pharmaceutical * S-1226: SolAeroMed Inc. * Benralizumab: AstraZeneca * Colistimethate sodium: Zambon SpA * BI 1291583: Boehringer Ingelheim * AP-PA02: Armata Pharmaceuticals * ARINA-1: Renovion Non-Cystic Fibrosis Bronchiectasis Route of Administration Non-Cystic Fibrosis Bronchiectasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as * Intravenous * Subcutaneous * Oral * Intramuscular Non-Cystic Fibrosis Bronchiectasis Molecule Type Non-Cystic Fibrosis Bronchiectasis Products have been categorized under various Molecule types, such as * Monoclonal antibody * Small molecule * Peptide Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics Assessment * Non-Cystic Fibrosis Bronchiectasis Assessment by Product Type * Non-Cystic Fibrosis Bronchiectasis By Stage and Product Type * Non-Cystic Fibrosis Bronchiectasis Assessment by Route of Administration * Non-Cystic Fibrosis Bronchiectasis By Stage and Route of Administration * Non-Cystic Fibrosis Bronchiectasis Assessment by Molecule Type * Non-Cystic Fibrosis Bronchiectasis by Stage and Molecule Type DelveInsight's Non-Cystic Fibrosis Bronchiectasis Report covers around 15+ products under different phases of clinical development like * Late-stage products (Phase III) * Mid-stage products (Phase II) * Early-stage product (Phase I) * Pre-clinical and Discovery stage candidates * Discontinued & Inactive candidates * Route of Administration Further Non-Cystic Fibrosis Bronchiectasis product details are provided in the report. Download the Non-Cystic Fibrosis Bronchiectasis pipeline report to learn more about the emerging Non-Cystic Fibrosis Bronchiectasis therapies [ https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Some of the key companies in the Non-Cystic Fibrosis Bronchiectasis Therapeutics Market include: Key companies developing therapies for Non-Cystic Fibrosis Bronchiectasis are - Insmed Incorporated, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici, Haisco Pharmaceutical, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, SolAeroMed, and others. Non-Cystic Fibrosis Bronchiectasis Pipeline Analysis: The Non-Cystic Fibrosis Bronchiectasis pipeline report provides insights into * The report provides detailed insights about companies that are developing therapies for the treatment of Non-Cystic Fibrosis Bronchiectasis with aggregate therapies developed by each company for the same. * It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Cystic Fibrosis Bronchiectasis Treatment. * Non-Cystic Fibrosis Bronchiectasis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. * Non-Cystic Fibrosis Bronchiectasis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. * Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Cystic Fibrosis Bronchiectasis market. The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. Download Sample PDF Report to know more about Non-Cystic Fibrosis Bronchiectasis drugs and therapies [ https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Non-Cystic Fibrosis Bronchiectasis Pipeline Market Drivers * Recent Developments to Improve Research into Bronchiectasis, emergence of Novel Drugs & Therapies with Great Market Potential are some of the important factors that are fueling the Non-Cystic Fibrosis Bronchiectasis Market. Non-Cystic Fibrosis Bronchiectasis Pipeline Market Barriers * However, challenges Associated with the Drug Delivery, regulatory & Economic Hindrance and other factors are creating obstacles in the Non-Cystic Fibrosis Bronchiectasis Market growth. Scope of Non-Cystic Fibrosis Bronchiectasis Pipeline Drug Insight * Coverage: Global * Key Non-Cystic Fibrosis Bronchiectasis Companies: NovaBiotics Ltd, Synspira Therapeutics, Parion Sciences, Chiesi Farmaceutic, CSL Behring, Haisco Pharmaceutical, SolAeroMed Inc., AstraZeneca, Zambon SpA, Boehringer Ingelheim, Armata Pharmaceuticals, Renovion, and others * Key Non-Cystic Fibrosis Bronchiectasis Therapies: NP339, Research Programme:NCFB, Research programme: mucolytic agents, CHF 6333, CSL787, HSK31858, S-1226, Benralizumab, Colistimethate sodium, BI 1291583, AP-PA02, ARINA-1, and others * Non-Cystic Fibrosis Bronchiectasis Therapeutic Assessment: Non-Cystic Fibrosis Bronchiectasis current marketed and Non-Cystic Fibrosis Bronchiectasis emerging therapies * Non-Cystic Fibrosis Bronchiectasis Market Dynamics: Non-Cystic Fibrosis Bronchiectasis market drivers and Non-Cystic Fibrosis Bronchiectasis market barriers Request for Sample PDF Report for Non-Cystic Fibrosis Bronchiectasis Pipeline Assessment and clinical trials [ https://www.delveinsight.com/sample-request/non-cystic-fibrosis-bronchiectasis-ncfb-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr ] Table of Contents 1. Non-Cystic Fibrosis Bronchiectasis Report Introduction 2. Non-Cystic Fibrosis Bronchiectasis Executive Summary 3. Non-Cystic Fibrosis Bronchiectasis Overview 4. Non-Cystic Fibrosis Bronchiectasis- Analytical Perspective In-depth Commercial Assessment 5. Non-Cystic Fibrosis Bronchiectasis Pipeline Therapeutics 6. Non-Cystic Fibrosis Bronchiectasis Late Stage Products (Phase II/III) 7. Non-Cystic Fibrosis Bronchiectasis Mid Stage Products (Phase II) 8. Non-Cystic Fibrosis Bronchiectasis Early Stage Products (Phase I) 9. Non-Cystic Fibrosis Bronchiectasis Preclinical Stage Products 10. Non-Cystic Fibrosis Bronchiectasis Therapeutics Assessment 11. Non-Cystic Fibrosis Bronchiectasis Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Non-Cystic Fibrosis Bronchiectasis Key Companies 14. Non-Cystic Fibrosis Bronchiectasis Key Products 15. Non-Cystic Fibrosis Bronchiectasis Unmet Needs 16 . Non-Cystic Fibrosis Bronchiectasis Market Drivers and Barriers 17. Non-Cystic Fibrosis Bronchiectasis Future Perspectives and Conclusion 18. Non-Cystic Fibrosis Bronchiectasis Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email:Send Email [ https://www.abnewswire.com/email_contact_us.php?pr=noncystic-fibrosis-bronchiectasis-pipeline-insights-2024-therapies-clinical-trials-and-key-companies-involved-by-delveinsight-insmed-inc-astrazeneca-zambon-csl-behring-chiesi-farmaceutici ] Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website: https://www.delveinsight.com/ This release was published on openPR.
Gerry Butts says Trudeau less likely to remain leader since Freeland quitShiitake Mushroom Market to Observe Prominent CAGR of 8.7% by 2029, Size, Share, Trends, Demand, Growth, Challenges and Competitive Outlook
With a new year ahead and the holiday fanfare behind, this is a great time to set money goals, especially if you recently spent a lot on gifts and travel and want to get your finances in shape. You’d be in good company, too — according to a January 2024 survey from the Pew Research Center, of the 30% of Americans who made at least one New Year’s resolution, 61% had a goal that was money-related. Right now, you may be highly motivated to solve every single one of your money issues in the next few months, but daily life is guaranteed to get in the way. Your financial to-do list, once so full of promise, can eventually get stuffed in the back of a drawer while you manage more pressing matters. The vast majority of New Year’s resolutions go unfulfilled. So how can you improve your odds of success? It comes down to accepting that you won’t have the time or energy to complete every task to perfection. Creating a system where you can prioritize, plan ahead and hold yourself accountable can help. Many start by setting a goal to trim frivolous costs, which can certainly be helpful, but there are other ways to make a big difference. Taylor Schult — a certified financial planner and founder of Define Financial, an advisory firm in San Diego — recommends starting with a few overlooked financial tasks. Freezing your credit is a quick, easy way to guard yourself against identity theft. It’s free to do, and you can temporarily lift the freeze when you’re applying for a loan or credit card. Schulte also suggests looking into umbrella insurance , which offers additional coverage beyond what your auto, homeowners and other insurance policies provide. This coverage can spare you from massive out-of-pocket costs in the event you get sued. Basic estate planning, including creating a will, is another thing to put high on your list. Putting off this task can create a major headache for your loved ones if something happens to you unexpectedly. “I know it’s a pain point and it’s often kicked down the road,” Schulte says. Paying attention to your spending is always important, but don’t neglect taking steps to protect your money, yourself and your loved ones. So many money goals are born out of social pressure. You “should” want to save up to own a home, even if you’re happily renting. You “should” sacrifice short-term needs and wants to stash away as much as possible for retirement, even though it leaves you feeling deprived. But money goals should be tied to the things that matter most to you. If they aren’t, you’ll quickly lose interest. “If you don’t know what goals to choose, go back to your values and have them guide the goals you set,” says Eric Roberge, a certified financial planner and founder of Beyond Your Hammock, a financial advisory firm in Boston. You can combine goal-setting with a little planning, so expenses are less likely to creep up on you throughout the year. Think about what expected costs will be coming up in the next six to 12 months, like recurring bills, vacations, anticipated home or car repairs, and other expenses. This approach allows you to set money aside each month to put toward planned costs, as well as longer-term goals. Forgetting your goals can be far too easy, so to make something stick, write it down . It can be as simple as a handwritten list you keep on the fridge, or online calendar reminders that will nudge you every so often. For time-sensitive goals, set deadlines. One tactic is to make multiple lists based on what you need to complete within the next week, month or three months. As time passes and you check off items, you can update the list. Enlist others’ help, too. Weekly or monthly household money meetings are useful if you’re completing financial tasks as a group. Or share your goals with a trusted friend or family member who can serve as an accountability partner. Looping in loved ones can help keep you on track. “We don’t mind letting ourselves down,” Schulte says. “But we hate to let other people down.” It’s easy to get stuck in decision-making mode when trying to pick a high-yield savings account, credit card or possible investments, but eventually, you need to make a good-enough choice . Taking action now can have more of a positive effect on your life than waiting until you’ve painstakingly considered each option. Roberge says that though he’d prefer to optimize every financial decision, he doesn’t because if he did, he wouldn’t get things done. “Everything in moderation is one of the things that I live by,” he says. “Going to extremes in any one thing, at the detriment of other things that are important, doesn’t work long-term.” More From NerdWallet Sara Rathner writes for NerdWallet. Email: srathner@nerdwallet.com . Twitter: @sarakrathner. The article Got Money Goals for the New Year? Stay on Track With These Tips originally appeared on NerdWallet.GCC-4001 is under clinical development by Artiva Biotherapeutics and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData, Phase II drugs for Peripheral T-Cell Lymphomas (PTCL) have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. GCC-4001 overview GCC-4001 (AB-101) is under development for the treatment of rheumatoid arthritis, systemic lupus erythematosus, pemphigus vulgaris, granulomatosis with polyangiitis and microscopic polyangiitis, B-cell non-Hodgkin lymphoma, relapsed or refractory chronic lymphocytic leukemia, diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, Waldenstrom Macroglobulinemia, peripheral T-cell lymphomas (PTCL), angioimmunoblastic T-cell lymphoma, anaplastic large cell lymphoma (ALCL), R/R classical Hodgkin lymphoma, lupus nephritis (LN) and autoimmune disorders. The therapeutic candidate is an allogeneic, non-engineered, cord blood-derived natural killer (NK) cell therapy. It is administered through intravenous route and is being developed based on AlloNK platform. Artiva Biotherapeutics overview Artiva Biotherapeutics is a biotechnology company developing allogeneic natural killer (NK) cell therapies to treat hematologic cancers or solid tumors. It is investigating AB-101, an allogeneic NK cell therapy used for the treatment of B-cell malignancies; AB-201, a CAR-NK (chimeric antigen receptor-modified natural killer) cell therapy targeting HER2 positive solid tumors; and AB-202 against CD19 positive B-cell malignancies. Artiva Biotherapeutics utilizes its proprietary CAR (chimeric antigen receptor) platform to improve NK cells’ therapeutic activity and tumor-targeting capability. Artiva Biotherapeutics is headquartered in San Diego, California, the US. For a complete picture of GCC-4001’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .TORONTO — Canada's main stock index pushed higher to end Monday up almost 150 points on light trading action, while U.S. stock markets also gained ahead of the Christmas break. "Today is a quiet pre-Christmas Day of trading," said Kevin Burkett, a portfolio manager at Victoria, B.C.-based Burkett Asset Management. While markets in both Canada and the U.S. were mild, Burkett suggests watching the markets closely during the holiday season, a contrast to what's typically a sleepy period for markets. "We're continuing to watch markets very closely here because you've got some tectonic plate shifting in terms of the macroeconomic backdrop," he said. "It's all the political conversations both in Canada and in the U.S." Burkett added fiscal policy seems to be disconnected from monetary policy in the post-pandemic period. "The fiscal policy may shift and that shift absolutely has market implications both in the short and long term," he said. The S&P/TSX composite index was up 149.50 points at 24,748.98. Statistics Canada released its latest numbers on Canada's economic growth, up 0.3 per cent in October — driven by the mining, quarrying, and oil and gas extraction sector. The loonie continued its slide, trading for 69.47 cents US compared with 69.61 cents US on Friday. The telecom sector was the biggest loser at the closing on TSX, which Burkett attributed to "tax loss selling happening at the end of the year." Competition Bureau Canada announced on Monday it was suing Rogers Communications Inc. for allegedly making misleading claims about its infinite wireless plans. The stock price for Rogers, which is hovering near 52-week lows, fell 0.7 per cent on Monday. Meanwhile, BCE was down almost 1.4 per cent and Telus dropped 0.9 per cent. Burkett suggested the day's poor performance among telecom companies was likely tax loss selling since it's almost the end of the year. "It's been a tough year for the communication services sector," he said. South of the border, communications services was the top-performing sector, led by large-cap tech companies. Several big technology companies helped support the gains, including chip companies Nvidia and Broadcom. In New York, the Dow Jones industrial average was up 66.69 points at 42,906.95. The S&P 500 index was up 43.22 points at 5,974.07, while the Nasdaq composite was up 192.29 points at 19,764.89. The February crude oil contract was down 22 cents at US$69.24 per barrel and the February natural gas contract was down six cents at US$3.35 per mmBTU. The February gold contract was down US$16.90 at US$2,628.20 an ounce and the March copper contract was down one cent at US$4.09 a pound. This report by The Canadian Press was first published Dec. 23, 2024. Companies in this story: (TSX: GSPTSE, TSX: CADUSD, TSE: BCE, TSE: RCI. B) Ritika Dubey, The Canadian Press
As TikTok bill steams forward, online influencers put on their lobbying hats to visit WashingtonIgor Sechin, a long-standing ally of President Vladimir Putin, will be staying as head of Russia’s largest oil producer Rosneft, for five more years, according to a company board decision disclosed on Friday. Sechin, known for his criticism of the Organization of the Petroleum Exporting Countries, has been the CEO of Rosneft since 2012. Sechin has been a close Putin ally since they met in the early 1990s on a trip to Brazil. Both men worked together in the St Petersburg mayor’s office and Sechin followed Putin to Moscow in 1996 where they rose through the Kremlin administration to the pinnacle of Russian power. While Putin was Kremlin chief from 2000 to 2008, Sechin served as his deputy chief of staff, and was branded as “the grey cardinal” of Russian politics by local media. After Putin left the Kremlin in 2008 to become prime minister, Sechin was named one of seven deputy prime ministers, taking on a more public role. In May 2012 he was appointed as Rosneft’s president. After Rosneft bought the Anglo-Russian TNK-BP oil firm in 2013 for $55 billion, Rosneft became the world’s top listed oil producer of the time. It produces around 4 million barrels per day, or some 4% of total global oil output. Source: Reuters (Reporting by Vladimir Soldatkin, Editing by Rosalba O’Brien)
Thursday, December 19, 2024 JFK Millennium Partners (JMP), selected by the Port Authority of New York & New Jersey (PANYNJ) to develop and operate the new Terminal 6 (T6) at John F. Kennedy International Airport, has issued a request for proposals (RFP) to procure a future all-electric fleet of ground support equipment (GSE). This initiative aligns with the terminal’s sustainability goals and is set to support T6 airlines and other partners when the state-of-the-art terminal opens in early 2026. Terminal 6 is a cornerstone of PANYNJ’s $19 billion transformation of JFK Airport into a world-class aviation gateway. This comprehensive overhaul includes the addition of two new terminals, upgrades to existing facilities, a modern ground transportation center, and a streamlined roadway network. JMP’s RFP invites vendors to provide electric-powered GSE currently available in the market, including essential equipment such as pushback units (both conventional and towbarless), baggage tugs, belt loaders, K-loaders, stair trucks, and more. Proposals must include charging infrastructure, maintenance, and repair services. The chosen provider will collaborate with JMP to design and implement charging infrastructure across T6’s designated areas. This shared all-electric fleet is integral to T6’s broader commitment to sustainability, aiming to reduce carbon emissions and eliminate reliance on fossil fuels throughout the terminal. Key environmental features at T6 include high-efficiency building systems, over 6,000 solar panels for renewable energy generation, stormwater capture and reuse systems, and a robust recycling program that diverts 90% of construction and operational waste, including asphalt, concrete, and steel. These efforts align with JMP’s objective to secure LEED* and ENVISION Gold certifications, recognized benchmarks for sustainable infrastructure. The all-electric GSE initiative also supports PANYNJ’s Net Zero Roadmap, a comprehensive plan to achieve agency-wide greenhouse gas emission reductions by 2050. This roadmap encompasses electric vehicle fleets, solar energy production, building decarbonization, and sustainable construction practices. Terminal 6 represents a significant leap toward a greener future for JFK Airport, setting a new standard for sustainability in global aviation. “Our fully-electric T6 ground fleet will play a critical role in our quest to deliver an outstanding new terminal that is sustainable by design, operationally efficient and makes use of all the latest technologies to help us exceed our sustainability goals,” said Steve Thody, CEO, JFK Millennium Partners. “We are excited to launch this RFP for an electric fleet of ground support equipment that will best serve our T6 airline partners, passengers, our airport community, and our planet for many years to come,” said Karen Ali, COO, JFK Millennium Partners. “We look forward to working with our future partner to create this new standard of operational excellence at JFK,” Ali added. In 2022, the Port Authority introduced the Zero-Emission Airside Vehicle (ZEAV) rule, mandating the transition to zero-emission ground service equipment (GSE) at the region’s three major airports. The rule requires the majority of the GSE fleet to achieve zero-emission status by 2030. To facilitate this transition, the Port Authority is providing charging infrastructure, ensuring GSE charging capabilities at all new gates, and collaborating with tenants on infrastructure planning. Interested parties wishing to participate in the electric ground support equipment RFP can contact the JMP procurement team for a copy of the RFP and additional details. The deadline for proposal submissions is January 17, 2025, and JMP anticipates selecting a provider by the first quarter of 2025.In a new poll , more than two-thirds of respondents said they believed denials of coverage and profits in the health insurance industry were partially responsible for the killing of Brian Thompson , the UnitedHealthcare CEO, in early December. Thompson was shot dead on the streets of Manhattan. His killer fled, sparking a nationwide manhunt, which ended when Luigi Mangione was arrested and charged with the killing after being arrested in a Pennsylvania McDonald’s. Mangione’s alleged writings indicated that he was angry at the US healthcare industry and saw it as exploitative. The executive’s death also saw an outpouring of expressions of public anger towards the healthcare industry, with many Americans on social media sharing stories of poor experiences at the hands of the US profit-based healthcare system. Almost 70% of respondents said “denials for health care coverage by health insurance companies” shared “a great deal” or a “moderate amount” of responsibility. Sixty-seven per cent said “profits made by health insurance companies” shared “a great deal” or a “moderate amount” of responsibility. Twenty per cent of respondents to the new poll said “the individual who committed the killing” bore “only a little” responsibility or “none at all” for the death of Thompson. On the other hand, 78% said that person bore “a great deal” or a “moderate amount” of responsibility. The poll, which was conducted by NORC at the University of Chicago, surveyed 1,001 participants from 50 states and the District of Columbia. The participants were all 18 years or older. The survey was conducted between 12 December and 16 December. According to the poll, Americans were tuned into news about the CEO’s killing, with 73% of respondents saying they either heard about the killing of the UnitedHealthcare CEO “a lot” or “some”. Twenty-seven per cent said they heard “only a little” or “nothing at all”. Fifty-eight per cent of respondents said they had never personally had an issue with their health insurance. Fifty-seven per cent said their immediate family had never had an issue and 53% say their close friends had never had an issue. But 15% say they had personally had a claim denied, 13% had had issues getting prior authorization, 16% had struggled to find a suitable provider within their covered network, and 7% did not have any health insurance. Forty-one per cent of respondents said that they were “not very concerned” or “not at all concerned” about “the possibility of further violence directed at health insurance executives or executives from other industries”, while 39% said they were “somewhat concerned”. Nineteen per cent said they were “extremely” or “very” concerned.How to buy Seattle Seahawks vs. Chicago Bears tickets
Lagging low-altitude economy 'can catch up by learning from the mainland'
(All times Eastern) Schedule subject to change and/or blackouts Monday, Dec. 23 COLLEGE BASKETBALL (MEN’S) 5:30 p.m. ESPNU — Diamond Head Classic: TBD, Consolation Semifinal, Honolulu 7 p.m. SECN — MTSU at Tennessee 8 p.m. ESPNU — Diamond Head Classic: TBD, Semifinal, Honolulu 10 p.m. BTN — Seattle at Washington 10:30 p.m. ESPN2 — Diamond Head Classic: TBD, Semifinal, Honolulu 12:30 a.m. (Tuesday) ESPN2 — Diamond Head Classic: TBD, Consolation Semifinal Honolulu COLLEGE FOOTBALL 11 a.m. ESPN — The Myrtle Beach Bowl: Coastal Carolina vs. UTSA, Conway, S.C. 2:30 p.m. ESPN — The Famous Idaho Potato Bowl: N. Illinois vs. Fresno St., Boise, Idaho NBA BASKETBALL 7 p.m. NBATV — San Antonio at Philadelphia 10 p.m. NBATV — Indiana at Golden State NFL FOOTBALL 8:15 p.m. ABC — New Orleans at Green Bay ESPN — New Orleans at Green Bay The Associated Press created this story using technology provided by Data Skrive TV listings provided by LiveSportsOnTV . Copyright 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.
A number of elected Mohave County officials, and their counterparts across the state, have significant pay raises to celebrate this holiday season. The salary increases take effect the first of the year. In Mohave County, nine positions will see their annual salaries increased from $63,800 to $83,800. They include each of the five Board of Supervisors posts, the Assessor, Treasurer, Recorder and School Superintendent. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.(All times Eastern) Schedule subject to change and/or blackouts Monday, Dec. 23 COLLEGE BASKETBALL (MEN’S) 5:30 p.m. ESPNU — Diamond Head Classic: TBD, Consolation Semifinal, Honolulu 7 p.m. SECN — MTSU at Tennessee 8 p.m. ESPNU — Diamond Head Classic: TBD, Semifinal, Honolulu 10 p.m. BTN — Seattle at Washington 10:30 p.m. ESPN2 — Diamond Head Classic: TBD, Semifinal, Honolulu 12:30 a.m. (Tuesday) ESPN2 — Diamond Head Classic: TBD, Consolation Semifinal Honolulu COLLEGE FOOTBALL 11 a.m. ESPN — The Myrtle Beach Bowl: Coastal Carolina vs. UTSA, Conway, S.C. 2:30 p.m. ESPN — The Famous Idaho Potato Bowl: N. Illinois vs. Fresno St., Boise, Idaho NBA BASKETBALL 7 p.m. NBATV — San Antonio at Philadelphia 10 p.m. NBATV — Indiana at Golden State NFL FOOTBALL 8:15 p.m. ABC — New Orleans at Green Bay ESPN — New Orleans at Green Bay The Associated Press created this story using technology provided by Data Skrive TV listings provided by LiveSportsOnTV .India, Kuwait ties elevated to strategic partnership during PM Modi’s visit: MEA